



This is a repository copy of *Availability, cost and affordability of essential medicines for smoking cessation in low-income and middle-income countries: a cross-sectional study*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/223292/>

Version: Published Version

---

**Article:**

Plum, C. [orcid.org/0009-0002-4623-8391](https://orcid.org/0009-0002-4623-8391), Stolbrink, M., Ozoh, O. et al. (4 more authors) (2025) Availability, cost and affordability of essential medicines for smoking cessation in low-income and middle-income countries: a cross-sectional study. *Thorax*. ISSN 0040-6376

<https://doi.org/10.1136/thorax-2024-222391>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>



OPEN ACCESS

# Availability, cost and affordability of essential medicines for smoking cessation in low-income and middle-income countries: a cross-sectional study

Catherine Plum ,<sup>1</sup> Marie Stolbrink,<sup>2,3</sup> Obianuju Ozoh,<sup>4,5</sup> Shamanthi Jayasooriya ,<sup>6</sup> Rebecca Nightingale ,<sup>7</sup> Kevin Mortimer,<sup>8,9,10</sup> David Halpin<sup>11</sup>

<sup>1</sup>University Hospitals of Morecambe Bay NHS Trust, Lancaster, UK

<sup>2</sup>Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

<sup>3</sup>Department of Pulmonology, Stellenbosch University, Stellenbosch, South Africa

<sup>4</sup>Department of Medicine, University of Lagos College of Medicine, Lagos, Nigeria

<sup>5</sup>Pulmonology, Lagos University Teaching Hospital, Surulere, Lagos, Nigeria

<sup>6</sup>Academic Unit of Primary Care, Medical Research Council The Gambia, Sheffield, UK

<sup>7</sup>Liverpool School of Tropical Medicine, Liverpool, UK

<sup>8</sup>Department of Pathology, University of Cambridge, Cambridge, UK

<sup>9</sup>Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa

<sup>10</sup>Respiratory Medicine, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

<sup>11</sup>Department of medicine, University of Exeter Medical School, Exeter, UK

## Correspondence to

Dr Catherine Plum;  
catherine.plum96@gmail.com

CP and MS are joint first authors.

KM and DH are joint senior authors.



© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.

**To cite:** Plum C, Stolbrink M, Ozoh O, *et al.* *Thorax* Epub ahead of print: [please include Day Month Year]. doi:10.1136/thorax-2024-222391

## ABSTRACT

Smoking cessation is more effective when supported by medicines. Data on the availability, cost and affordability of these treatments in low-income and middle-income countries (LMIC) are limited. Cross-sectional data for smoking cessation medications were collected from pharmacies, healthcare facilities and central medicine stores in 60 LMIC (2022–2023). Medications had varying availability, large price ranges and were essentially unaffordable. Enabling access to these medications is important in reducing tobacco consumption and associated disease. Strategies for integrating smoking cessation services into health systems are needed to reach Sustainable Development Goal targets.

## INTRODUCTION

The WHO Sustainable Development Goals (SDG) target a reduction in tobacco consumption by 30% by 2025, as part of the strategy to reduce premature deaths from non-communicable disease by a third by 2030.<sup>1</sup> The WHO MPOWER measures outline ways to reduce tobacco consumption, including ‘offering help to quit’.<sup>2</sup> Over 80% of tobacco smokers live in low-income and middle-income countries (LMIC),<sup>3</sup> and smoking cessation medications should be accessible and affordable to all.<sup>4</sup>

Smoking cessation medications including nicotine gums, transdermal patches, bupropion and varenicline tablets have been on the WHO ‘Model List of Essential Medicines’ (EML) since 2009, based on their efficacy, cost-effectiveness and safety.<sup>5</sup> Evidence on the availability, cost and affordability of these treatments in LMIC is limited. This study provides high-quality data describing the current accessibility of these medications in LMIC.

## METHODS

Healthcare professionals in LMIC completed a survey on the availability and cost of smoking cessation medications from three facility types: a pharmacy, healthcare facility (HCF) and central medicine store (CMS, online supplemental appendix). Collaborators were recruited through professional networks and snowballing. Supply for 1 month’s treatment was based on average cigarette consumption of 10/day.<sup>6</sup> Prices for 1 month’s treatment were compared. A medicine was considered affordable if 1 month’s treatment cost less than 1 day’s wage of the lowest paid government worker,

defined by local minimum wage.<sup>7</sup> Global varenicline supply was interrupted in 2021, so it was not explored in this study.<sup>8</sup> This survey was nested in the *Thorax*-published study on the accessibility of chronic respiratory disease medicines (online supplemental appendix).<sup>9</sup>

## RESULTS

Data were reported from 60 countries, representing 84% of the global LMIC population. Information from pharmacies, HCFs and CMSs was available from 57, 56 and 46 countries, respectively. Most pharmacies were private (51/60), and more HCFs were public (45/60). There were 18 low-income (LIC), 24 low-middle-income, 17 upper-middle-income (UMIC) countries; Venezuela was unclassified (online supplemental appendix). Africa was the best-represented region with 26/60 countries.

## Nicotine gum

Nicotine gum was available in 20/57 pharmacies, 5/56 HCFs and 4/46 CMSs. Doses ranged from 2 to 4 mg (table 1, figure 1, online supplemental appendix). Price was provided by 19/20 pharmacies, 5/5 HCFs and 2/4 CMSs. The median (IQR) cost was US\$96 (US\$65.13–123.98), US\$61.94 (US\$55.88–89.05) and US\$65.72 (US\$11.44–120.00) in pharmacies, HCFs and CMSs, respectively. It was unaffordable from all facilities that provided price information (figure 1, online supplemental appendix).

## Nicotine patch

Nicotine transdermal patches were available in 13/57 pharmacies, 6/56 HCFs and 5/46 CMSs (table 1, online supplemental appendix). Doses ranged from 1 to 21 mg. Price was provided by 13 pharmacies, five HCFs and three CMSs. The median (IQR) cost was US\$62.09 (US\$51.54–100.90), US\$68.61 (US\$43.80–307.31) and US\$43.72 (US\$12.00–124.29) in pharmacies, HCFs and CMSs, respectively. It was affordable in one pharmacy (China) (figure 1, online supplemental appendix).

## Bupropion tablets

Bupropion 150 mg tablets were available in 2/57 pharmacies, 2/56 HCFs and 2/46 CMSs. Two pharmacies and two HCFs gave price information. The median (IQR) cost of tablets was US\$143.89 (US\$–151.15) and US\$25.10 (US\$24.26–25.94) in

**Table 1** Comparisons of availability, cost and affordability of WHO EML medicines for smoking cessation in LMIC

Facility	Survey measurement	Smoking cessation medications		
		Nicotine gum (2 mg, 4 mg)	Nicotine transdermal patch (15–30 mg/16 hours; 7–21 mg/24 hours)	Bupropion tablets (150 mg)
Pharmacy	Availability	20/57	13/57	2/57
	Median cost (IQR, US\$)	96 (65.13–123.98)	62.09 (51.54–100.90)	143.89 (129.38–158.40)*
	Median DOW (IQR)	10.35 (5.74–51.07)	5.84 (3.16–40.03)	31.76 (6.37–57.16)*
HCF	Availability	5/56	6/56	2/56
	Median cost (IQR, US\$)	61.94 (55.88–89.05)	68.61 (43.80–307.31)	25.10 (23.42–26.78)*
	Median DOW (IQR)	3.81 (3.26–7.70)	27.78 (3.01–60.53)	1.38 (1.32–1.43)*
CMS	Availability	4/46	5/46	1/46
	Median cost (IQR, US\$)	65.72 (11.44–120.00)	43.72 (12.00–124.29)	NIA

Cost: Supply for one month's treatment was guided by average daily cigarette consumption in LMIC of 10 cigarettes/day. One month's supply of nicotine gums was 10 gums/day, 30 transdermal patches (1 patch/day) and for bupropion 60 tablets/month based on average maintenance dose. Affordability was not calculated for CMSs as their prices were wholesale prices.

\*IQR could not be calculated due to missing information on price so results given as median (minimum-maximum).

CMS, central medicine store; DOW, days of work required to pay for 1 month's treatment; HCF, healthcare facility; LMIC, low-income and middle-income countries; NIA, no information available.

pharmacies and HCFs, respectively. Bupropion was unaffordable from all facilities that provided price information (table 1, figure 1, online supplemental appendix).

## DISCUSSION


This survey provides up-to-date, high-quality data on the availability, cost and affordability of smoking cessation medications globally and is the largest cross-sectional study on this topic in LMIC to date. Data came from a variety of income levels and 16 out of 20 of the most populous LMIC.

WHO EML medications for smoking cessation were not widely available and were largely unaffordable for those living in LMIC. The most available form was nicotine gum, and the least available was bupropion. All pharmacotherapies were more available in UMIC (online supplemental appendix, table 2). Our data showed wide variability in price.

Medicines were more available in pharmacies but more expensive (table 1), which is likely to be an accessibility barrier.

Results showed that these medications were mostly unaffordable, especially as treatment typically lasts at least 3 months. From our data, the median cost for 1 month of cigarettes is US\$12.27 (IQR US\$7.71–21.23) (online supplemental appendix), cheaper than the cost of any medication to support smoking cessation (table 1). The latest WHO report suggests that LMIC needs to raise taxes and prices of cigarettes.<sup>10</sup> Our data show the importance of coordinated implementation of the MPOWER measures as 'offering to help quit' is economically undermined if cigarettes remain more affordable than treatment.

The strengths of the study were the wide range of included LMIC and the actual determination of availability and cost by health professionals. There were some limitations including sampling bias towards urban, large centres. Participants were asked to enter the cheapest price of gum, patch and tablet per facility, so there could be more price variety and higher median



**Figure 1** Availability and affordability of nicotine gum, nicotine patches and bupropion by region.

**Table 2** Availability of WHO EML medications for smoking cessation by World Bank country income level

Medication	Availability	Low-income country (n=18)	Low-middle-income country (n=24)	Upper-middle-income country (n=17)
Nicotine gum (2 mg, 4 mg)	Pharmacy	5	5	10
	HCF	0	1	4
	CMS	0	1	3
Nicotine transdermal patch (15–30 mg/16 hours; 7–21 mg/24 hours)	Pharmacy	3	2	8
	HCF	0	3	4
	CMS	0	2	3
Bupropion tablets (150 mg)	Pharmacy	0	1	1
	HCF	0	0	2
	CMS	0	0	2

Pharmacies n=57 LMIC, HCF n=56 LMIC, CMS n=46 LMIC. Venezuela was not classified.  
CMS, central medicine store; HCF, healthcare facility; LMIC, low-income and middle-income countries.

costs. Information on prices of tablets from HCFs and CMSs was limited and some facilities had missing data. Since data collection, there has been an update to the WHO EML in July 2023, which now includes other forms of nicotine replacement therapy; lozenges and oral spray.

## CONCLUSION

Everyone globally should have the best support in stopping smoking, but without medications chances of successful smoking cessation are reduced. Our data can be used to inform smoking cessation programmes in LMIC, and combining this with other strategies will be key in achieving the greatest success for the individuals, as well as global targets in disease reduction.

X Shamanthi Jayasooriya @de\_shami

**Collaborators** Chronic Respiratory Disease Medicines Survey Investigators: Eris Mesonjesi, Nadia Ait-Khaled, Samya Taright, Santiago Larrateguy, Sanela Domuz Vujnovic, Carolina Barbosa Souza Santos, Abdoul Risgou Ouédraogo, Bertrand Hugo Mbatchou-Ngahane, Lydie Mboumi, Yanping Liu, Fu-Qiang Wen, Xi Yan, Yutian Zhang, Patrick Katoto, Arsene Daniel Nyalundja, Efraín Sánchez-Angarita, Maged Hassan, Magda Afifi, Willie Siduna, Amsalu Binegdie, Babatunde Awokola, Rafiuk Cosmos Yakubu, Magassouba Aboubacar Sidiki, Suyapa Sosa, Sarbjeet Khurana, Bony Wiem Lestari, Faisal Yunus, Antonia Morita Iswari Saktiawati, Mohammed Reza Masjedi, Hashim Talib Hashim, Peter Owiti, Shaiirbek Sulaimanov, Lawrence Oyewusi, Boshra Abusahmin, Mohamed Hadi Mohamed Abdelhamid, Felix Mkandawire, Ee Ming Khoo, Ousmane Ibrahim Diabate, Adrian Rendon, Berenice Soto-Moncivais, Bolykhan Baigaby, Celso Khosa, Cynthia Silva, Rajan Paudel, Karolinska Institutet, Alberto Piubello, Kadri Sani, Temitope Fapohunda, Olayinka Adeyeye, Valentina Cvejaska Cholakovska, Ghulam Mustafa, Javier Cabrera-Sanchez, Diana Deleanu, Jean Pierre Sibomana, Momar Mbodji, Vesna Vekovic, Zorica Zivkovic, Osman Muhyadin Abdulle, Brian Allwood, Babiker Adam, Sisira Siribaddana, Rana Ahmed, Mahdia Elhadi, Mohamed Elmustafa, Yousser Mohammad, Stellah Mpagama, Bibie Said, Mongkol Lao-Araya, Benilda Trias de Gula, Agnes Hamzaoui, Kübra Tunçel, Islam SangarTuğçe Tayyar, Aygün Gürgöze, Rebecca Nantanda, Jamilah Meghji, Maria Montes de Oca, Juan Catari, Tran Thien Quan Vu, Mohammed Mohammed, Ruba Khaled, Weiam Hussein, Charles Mataya Mphuka, Terrence Rudado Musekiwa.

**Contributors** MS and KM devised the study. UO, SJ, DMGH, RN and CP provided input on the protocol. All investigators contributed to data collection. CP completed the analysis with MS, and both assessed and verified the data. CP and MS wrote a first draft, with input from KM, UO, SJ, DMGH and RN. All investigators were invited

to comment on a second draft. All had full access to all the data in the study and had the final responsibility to submit for publication. KM is the guarantor author.

**Funding** The study was funded by MS Wellcome Trust Clinical PhD fellowship.

**Map disclaimer** The inclusion of any map (including the depiction of any boundaries therein), or of any geographic or locational reference, does not imply the expression of any opinion whatsoever on the part of BMJ concerning the legal status of any country, territory, jurisdiction or area or of its authorities. Any such expression remains solely that of the relevant source and is not endorsed by BMJ. Maps are provided without any warranty of any kind, either express or implied.

**Competing interests** KM reports advisory board fees from AstraZeneca and GlaxoSmithKline. No other competing interests.

**Patient consent for publication** Not applicable.

**Ethics approval** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

## ORCID iDs

Catherine Plum <http://orcid.org/0009-0002-4623-8391>

Shamanthi Jayasooriya <http://orcid.org/0000-0002-1147-5744>

Rebecca Nightingale <http://orcid.org/0000-0001-5636-8531>

## REFERENCES

- World Health Organisation. Regional office for Europe, tobacco control and sustainable development goals. Available: [https://cdn.who.int/media/docs/librariesprovider2/euro-health-topics/tobacco/tobacco-control-and-the-sustainable-development-goals\\_edited.pdf#:~:text=WHO%20sets%20out%20the%20specific%20tobacco-related%20target%20of,others%20to%20continuing%20action%2C%20as%20recommended%20by%20WHO](https://cdn.who.int/media/docs/librariesprovider2/euro-health-topics/tobacco/tobacco-control-and-the-sustainable-development-goals_edited.pdf#:~:text=WHO%20sets%20out%20the%20specific%20tobacco-related%20target%20of,others%20to%20continuing%20action%2C%20as%20recommended%20by%20WHO) [Accessed 6 Oct 2023].
- World Health Organisation. Tobacco: Framework convention on tobacco control, 2017. Available: <https://www.who.int/news-room/questions-and-answers/item/tobacco-and-the-who-framework-convention-on-tobacco-control>
- Shankar A, Parascandola M, Sakthivel P, et al. Advancing Tobacco Cessation in LMICs. *Curr Oncol* 2022;29:9117–24.
- World Health Organisation. WHO releases first-ever clinical treatment guideline for tobacco cessation in adults. 2024. Available: <https://www.who.int/news/item/02-07-2024-who-releases-first-ever-clinical-treatment-guideline-for-tobacco-cessation-in-adults>
- WHO. Model List of Essential Medicines, 22nd list. Medications for disorders due to psychoactive substance use. 2021. Available: <https://www.who.int/publications/i/item/9789240077164>
- Theilmann M, Lemp JM, Winkler V, et al. Patterns of tobacco use in low and middle income countries by tobacco product and sociodemographic characteristics: nationally representative survey data from 82 countries. *BMJ* 2022;378:e067582.
- International Labour Organization. International labour organization - statistics on wages. Geneva, Switzerland: United Nations; 2023. Available: <https://ilostat.ilo.org/topics/wages/.7/10/2023>
- Lang AE, Berlin I. The lancet, unavailability of varenicline: a global tragedy against the tobacco epidemic. 2023. Available: <https://www.thelancet.com/action/showPdf?pii=S2213-2600%2823%2900184-4> [Accessed 18 Oct 2023].
- Stolbrink M, Ozoh OB. Halpin DMG Chronic Respiratory Diseases Medicines Survey Investigators Collaboration, et al. Availability, cost and affordability of essential medicines for chronic respiratory diseases in low-income and middle-income countries: a cross-sectional study. *Thorax* 2024;79:676–9.
- World Health Organisation. WHO report on global tobacco epidemic 2023. 2023. Available: <https://www.who.int/publications/i/item/9789240077164>